Holen Sie sich die Stockscreener-App
2.30
0.43%
-0.01
Schlusskurs vom Vortag:
$2.31
Offen:
$2.28
24-Stunden-Volumen:
395.43K
Relative Volume:
0.70
Marktkapitalisierung:
$98.78M
Einnahmen:
$88.55M
Nettoeinkommen (Verlust:
$-53.21M
KGV:
-1.7776
EPS:
-1.2939
Netto-Cashflow:
$-29.48M
1W Leistung:
+6.48%
1M Leistung:
+69.74%
6M Leistung:
+52.82%
1J Leistung:
+52.32%
1-Tages-Spanne:
$2.28
$2.39
1-Wochen-Bereich:
$2.16
$2.485
52-Wochen-Spanne:
$1.13
$2.89
Pulmonx Corp Stock (LUNG) Company Profile
Firmenname
Pulmonx Corp
Sektor
Branche
Telefon
650-364-0400
Adresse
700 CHESAPEAKE DRIVE, REDWOOD CITY
Compare LUNG vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LUNG
Pulmonx Corp
|
2.30 | 99.21M | 88.55M | -53.21M | -29.48M | -1.2939 |
ABT
Abbott Laboratories
|
114.14 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
327.70 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.30 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.37 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.83 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pulmonx Corp Stock (LUNG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-03-10 | Eingeleitet | D. Boral Capital | Buy |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-06-04 | Eingeleitet | Lake Street | Buy |
| 2024-02-23 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-05 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-01-03 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2021-12-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-04-01 | Eingeleitet | Citigroup | Buy |
| 2021-03-25 | Eingeleitet | Piper Sandler | Neutral |
| 2021-03-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-10-26 | Eingeleitet | BofA Securities | Buy |
| 2020-10-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-10-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-10-26 | Eingeleitet | Stifel | Buy |
| 2020-10-26 | Eingeleitet | Wells Fargo | Equal Weight |
Alle ansehen
Pulmonx Corp Aktie (LUNG) Neueste Nachrichten
Pulmonx Corp (NASDAQ: LUNG) Share Price, LUNG Stock News, LUNG Share Price & Updates - Kalkine
Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year - MarketBeat
What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Morgan Stanley (LUNG) reports 6.9% Pulmonx stake in updated ownership filing - Stock Titan
Pulmonx at Canaccord Genuity growth conference: turnaround gains pace - Investing.com
Pulmonx (LUNG) Q2 2026 Earnings Call Transcript - The Globe and Mail
Pulmonx Corp 2026: Revenue $22.76M, EPS ($0.24) — 10-Q Summary - TradingView
Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Earnings Release: Here's Why Analysts Cut Their Pulmonx Corporation (NASDAQ:LUNG) Price Target To US$3.40 - Sahm
LUNG Looks 82.5% Undervalued on GF Value™ Despite Financial Chal - GuruFocus
Pulmonx Target of Unusually Large Options Trading (NASDAQ:LUNG) - MarketBeat
Earnings call transcript: Pulmonx tops Q2 2026 estimates, shares jump 14.4% - Investing.com
Pulmonx Affirms FY26 Sales Guidance of $90.000M-$92.000M - scanx.trade
Pulmonx's Aug. 11 Boston fireside chat will be webcast live - Stock Titan
LUNG|Pulmonx Corp|Price:1.225|Chg%:+0.055 - TradingKey
Pulmonx Corp (LUNG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pulmonx Corp expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Pulmonx Reports Q1 2026 Earnings with Strategic Outlook - Intellectia AI
Pulmonx Market Sentiment - Benzinga España
Pulmonx Corp. Revenue Breakdown – MUN:4NI - TradingView
Pulmonx Corp (LUNG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pulmonx Corp (LUNG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pulmonx Corp (LUNG) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pulmonx Corp (LUNG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pulmonx Corp (LUNG) Cash Flow - TradingKey
TradingKey - TradingKey
LUNG|Pulmonx Corp|Price:2.305|Chg%:+0.265 - TradingKey
Pulmonx (LUNG) Projected to Release Earnings on Wednesday - MarketBeat
Pulmonx Sets July 29 Webcast to Discuss Second-Quarter Results - Stock Titan
Pulmonx Corp (LUNG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pulmonx (NASDAQ:LUNG) Sparks Fresh Penny Stock Buzz - Kalkine Media
Pulmonx Corp highlights lung device strategy as a specialized medtech player - ad-hoc-news.de
Price to sales forward of Pulmonx Corporation – NASDAQ:LUNG - TradingView
Enterprise value to EBIT forward of Pulmonx Corporation – NASDAQ:LUNG - TradingView
Enterprise value to EBITDA forward of Pulmonx Corp. – LSX:A2P1AF - TradingView
Price to earnings forward of Pulmonx Corp. – LSX:A2P1AF - TradingView
Price to sales forward of Pulmonx Corp. – DUS:4NI - TradingView
Pulmonx Corp highlights its respiratory device portfolio as investors assess long-term growth prospe - Ad Hoc News
LUNG News | PULMONX CORP (NASDAQ:LUNG) - ChartMill
Pulmonx Corp. Actuals & Estimates (NASDAQ:LUNG) - TradingView
Pulmonx Corp (LUNG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pulmonx Corp (LUNG) Institutional Confidence - TradingKey
Pulmonx Corp (LUNG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
LUNG SEC FilingsPulmonx Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Pulmonx (LUNG) awards 40,000 restricted stock units to director - Stock Titan
Director Ferrari (LUNG) awarded 40,000 Pulmonx restricted stock units - Stock Titan
Pulmonx Corp (LUNG) director granted 40,000 restricted stock units - Stock Titan
[Form 4] Pulmonx Corp Insider Trading Activity - Stock Titan
Pulmonx (LUNG) director receives 40,000-share RSU stock grant - Stock Titan
Don't Ignore The Insider Selling In Pulmonx - Sahm
Pulmonx (NASDAQ: LUNG) investors back board, auditor and executive pay - Stock Titan
Finanzdaten der Pulmonx Corp-Aktie (LUNG)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.76%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):